Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Impact of Beta-2 Adrenergic Blockade With Checkpoint Inhibition in Checkpoint Inhibitor Refractory Metastatic Triple Negative Breast Cancer

NCT05741164 is registered in ClinicalTrials.gov with Emory University as lead sponsor.

NCT NCT05741164
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05741164 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Impact of Beta-2 Adrenergic Blockade With Checkpoint Inhibition in Checkpoint Inhibitor Refractory Metastatic Triple Negative Breast Cancer
Lead sponsor
Emory University
Phase
Phase 2
Overall status
Recruiting
Start date
September 1, 2024
Completion date
June 30, 2029
Enrollment
37 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

anatomic stage iii breast cancer ajcc v8, anatomic stage iv breast cancer ajcc v8, metastatic triple-negative breast carcinoma, refractory triple-negative breast carcinoma, unresectable triple-negative breast carcinoma